Novartis AG
IL-17 ANTAGONISTIC ANTIBODIES
Last updated:
Abstract:
An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.
Status:
Application
Type:
Utility
Filling date:
15 May 2019
Issue date:
5 Sep 2019